NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at top European Conference on Exosomes and Regenerative Medicine
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
Gross Proceeds close of $4M CAD Generated for NurExone from Warrants Exercise
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
Submission of OTCQB Listing Application to Initiate US financial presence
NurExone establishing Research and Development Facility in Haifa, Israel
NurExone Presenting Regulatory Pathways for Exosomes Therapies at Global Summit
NurExone's Intellectual Property portfolio is expanding to encompass processes and compositions related to exosomes in large-scale production
NurExone Biologic launches licensing efforts for its ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.